UPDATE: Jazz Pharmaceuticals to acquire GW Pharma for $7.2 billion in cash and stock, GW soars 46% premarket - MarketWatch

Jazz Pharmaceuticals Plc JAZZ, -5.82% said Wednesday it has agreed to acquire GW Pharmaceuticals Plc GWPH, +46.16% in a cash-and-stock deal valued at $7.2 billion. Under the terms of the deal, Jazz Pharma will pay $200 per share in cash and $20 in stock for each share owned, or a premium of about 50% over GW's closing price on Tuesday, and 60% over its 30-day volume weighted average price. The deal is expected to close in the second quarter, to boost profit in the first year after close and to drive double-digit revenue growth. GW is a leader in therapies based on its proprietary cannabinoid product platform to treat a number of diseases. The company was the first to receive FDA approval for a CBD-based treatment for severe forms of childhood epilepsy in its Epidiolex lead product. Jazz makes sleep medications and has a growing oncology business. GW Pharma shares soared 46% premarket after resuming trade following a halt for the news. Jazz shares were down 2.7% premarket, but have gained 11% in the last 12 months, while the S&P 500 SPX, -0.01% has gained 18%.

Let's block ads! (Why?)

https://news.google.com/__i/rss/rd/articles/CBMid2h0dHBzOi8vd3d3Lm1hcmtldHdhdGNoLmNvbS9zdG9yeS9qYXp6LXBoYXJtYWNldXRpY2Fscy10by1hY3F1aXJlLWd3LXBoYXJtYS1mb3ItNzItYmlsbGlvbi1pbi1jYXNoLWFuZC1zdG9jay0yMDIxLTAyLTAz0gF7aHR0cHM6Ly93d3cubWFya2V0d2F0Y2guY29tL2FtcC9zdG9yeS9qYXp6LXBoYXJtYWNldXRpY2Fscy10by1hY3F1aXJlLWd3LXBoYXJtYS1mb3ItNzItYmlsbGlvbi1pbi1jYXNoLWFuZC1zdG9jay0yMDIxLTAyLTAz?oc=5

2021-02-03 13:13:00Z
52781350849069